Arsenal Capital Partners has purchased Synchrogenix for an undisclosed amount. The New York firm is one of many PE shops benefitting from a favorable fundraising environment, and closed an $875 million fund in April 2013. 

Wilmington, Del.-based Synchrogenix provides regulatory writing and related services to pharmaceutical, biotechnology and medical device companies.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.